Search hospitals > Texas > Houston

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Claim this profile
Houston, Texas 77030
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Leukemia
Conducts research for Lymphoma
295 reported clinical trials
47 medical researchers
Photo of Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center in HoustonPhoto of Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center in Houston

Summary

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 497 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.

Area of expertise

1Cancer
Global Leader
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center has run 78 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II
2Tumors
Global Leader
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center has run 70 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Breast Cancer
Cancer
Osteosarcoma
Non-Small Cell Lung Cancer
Brain Tumor
Rhabdomyosarcoma
Lung Cancer
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Lymphoma
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center?
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 497 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.